Navigation Links
Drop Patent Petition, Activists Ask Novartis

Seeking to keep the price of a cancer drug affordable for masses, activists from several countries Monday gathered here and asked Swiss pharmaceutical major Novartis// to withdraw its case against the Indian government that has not granted patent to its anti-cancer medicine.

"India produces affordable medicines that help millions of people both here and in many other developing countries. A patent grant to Novartis on Gleevec will certainly make cancer medicine unaffordable for the poor," said Amit Sengupta, joint convenor of the PEOPLE'S Health Movement.

"While a generic drug for cancer costs Rs.8,000 for one month of treatment, Gleevec costs Rs.120,000. If Novartis gets the patent, then generic drugs will not be available in market," Sengupta told reporters.

In May 2006, Novartis had filed two cases against the government of India and the Cancer Patients Aid Association (CPAA) challenging the rejection of its patent application under the Indian Patent Law.

The company's application for a patent on Gleevec was opposed by the CPAA and subsequently rejected by the Chennai patent office in January 2006.

The application was rejected as it claimed Gleevec to be only a new form of an old drug and not an invention.

Unni Karunakara, medical director of the Medicins Sans Frontieres, a Netherlands-headquartered organisation, said that India is the main supplier of essential medicines for developing countries. Sixty-seven percent of the medicines produced in India are exported to developing countries, he said.

"A patent grant to Novartis will not only affect people in India but also millions of people in developing countries. It will set a wrong precedent for frivolous applicants to get patent by just tinkering molecules. Innovations of drugs will become difficult," Karunakara said.

"General public cannot afford the second line drugs as their cost will increase between seven to 30 times, " he added.

Michel Lotrowski, a Brazilian activist, said Novartis was embarking on sheer profiteering without even thinking of public health conditions.

K.M. Gopakumar, a member of the Centre for Trade and Development, said Novartis had challenged Section 3-D of the Indian Patent Act that dismisses frivolous patent applications as incongruous.

"Does the multinational want to say that the Indian government should frame law keeping in mind Novartis' profit motive? Can't we stop frivolous patent applications from seeing light?" Gopakumar asked.

Source-IANS
'"/>




Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Patent for Seminal RNAi innovation Cleared in Australia
9. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. A Patented Device for Rapid Diagnosis of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: